ETON

Eton Pharmaceuticals, Inc. (ETON) 10Y Growth Potential Analysis (2026)

Invetso Score: 5.8/10 — Balanced · Last Updated: 2026-08-01

Overall Score

Growth Runway

ETON still shows a high-growth profile with revenue per share of 3.82 and strong profitability metrics supporting continued expansion potential.

Return on equity is 40.1% and return on invested capital is 20.4%, indicating the business can compound capital efficiently.

Financial Strength

Liquidity remains acceptable with a current ratio of 1.52 and quick ratio of 1.30.

Leverage is modest with debt-to-equity at 0.62 and net debt to EBITDA at 0.12, suggesting limited balance-sheet stress.

Profitability Quality

Gross margin is 57.9% and net margin is 12.0%, showing solid underlying economics.

Operating margin of 15.4% and interest coverage of 6.1x indicate the company is converting sales into earnings reasonably well.

Cash Generation

Free cash flow yield is only 0.9% and price-to-free-cash-flow is elevated at 114.3x, limiting near-term cash-return appeal.

Operating cash flow remains positive, but free cash flow per share of 0.53 is modest relative to the valuation.

Valuation

Valuation remains stretched with price-to-earnings at 132.2x and price-to-sales at 15.9x.

Enterprise value to EBITDA of 90.8x implies the market is pricing in substantial future growth.

Sources

  • Company filings (10-K, 10-Q, investor presentations)
  • Financial and market data providers
  • Public news and industry information

🔒 Go Beyond This Framework

This is one of 10 institutional-grade frameworks Invetso runs on Eton Pharmaceuticals, Inc.. Unlock the complete analysis — SWOT, Economic Moat, Porter’s Five Forces, Management, PESTLE and the Invetso Quality Score.

Create your free account on Invetso →